Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets

Yufang Shi,Liming Du,Liangyu Lin,Ying Wang

DOI: https://doi.org/10.1038/nrd.2016.193

IF: 112.288

2016-01-01

Nature Reviews Drug Discovery

Abstract:Key Points Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, actively contribute to the formation of the tumour microenvironment, wherein they are converted into tumour-associated MSCs (TA-MSCs). TA-MSCs regulate tumour growth, metastasis and responses to chemotherapy and radiotherapy by producing growth factors, chemokines and cytokines. TA-MSCs have an important role in regulating tumour immunity. Blocking TA-MSC-associated immunosuppressive factors could unleash antitumour immune responses. Novel antitumour therapeutic strategies can be developed by targeting TA-MSC-produced factors that promote tumour growth, metastasis and drug resistance. Owing to their tumour-tropic nature, in vitro -expanded MSCs can be genetically engineered to express antitumour agents at the tumour site to specifically kill tumour cells or to enhance antitumour immune responses.